Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
June 11, 2018WILMINGTON, Del. - NeuroRx, Inc., a clinical stage biopharma company has completed the feasibility enrollment phase of its 2b/3 clinical trial of NRX-101 for the treatment of suicidal bipolar...
-
May 7, 2018FDA deems proposed Phase 2b/3 trial adequate to support a regulatory submission
WILMINGTON, Del., May 07, 2018 -- NeuroRx, a clinical stage biopharmaceutical company developing the first drug regimen to treat Severe Bipolar Depression in patients with Acute Suicidal Ideation...
-
January 3, 2018Company to present at J.P. Morgan Healthcare Conference in San Francisco January 10th, 2018
NeuroRx, a clinical stage biopharma company developing the first drug regimen to treat Severe Bipolar Depression in patients with Acute Suicidal Ideation & Behavior (ASIB), announced that it has...
-
December 27, 2017Third clinical research site for NRX-100 / NRX-101 phase 2B/3 clinical study
NeuroRx, a clinical stage biopharma company developing the first drug regimen to treat severe bipolar depression in patients with Acute Suicidal Ideation and Behavior (ASIB), announced that it has...
-
September 6, 2017Company to present at Rodman and Renshaw Global Investment Conference in New York City on Sept 12, 2017
NeuroRx, a clinical stage biopharma company developing the first oral therapy for Acute Suicidal Ideation and Behavior (ASIB), has been granted Fast Track status by the US Food and Drug...
Click here to view our corporate presentation or on the image below
 |
